2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metasta…

Memorial Sloan Kettering Cancer Center

M. Hwang

Year in Review: Precision Medicine

Vivek Subbiah

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

2024 ASCO® Annual Meeting Insights Hub

T. Mok

ADCs and Bispecific Inhibitors in NSCLC

Chul Kim

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

UCSF School of Medicine

H. Kang

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

John Conibear

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

An Update on Lung Cancer Targeted Therapies: The Evolution of Person…

University of Miami Sylvester Comprehensive Cancer Center

E. Rodriguez

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Insights from 2023 ESMO Annual Meeting

N. Girard